Coronavirus Drug Discovery, Volume 1: SARS-CoV-2 (COVID-19) Prevention, Diagnosis, and Treatment is the first of three volumes presenting comprehensive information on drug discovery against COVID-19. This volume provides background information on the genesis of COVID-19, the epidemiology, transmission, pathogenesis, and mutagenesis. It also presents the various treatment options, drug discovery opportunities and vaccine developmental processes. Written by global team of experts from key institutions across the globe, this book is recommended to all concerned agencies, private research firms, and consortiums working on finding a solution to COVID-19 and its variants. By design, this book will be useful to drug developers, medicinal chemists, pharmacologists, health experts, researchers, students and faculty members in industry and academia. - Presents information on the genesis of COVID-19, global impact and collaborative efforts - Details the epidemiology, transmission, pathogenesis, and mutagenesis of SARS-CoV-2 - Documents the various treatment options and vaccine development for COVID-19

This book tackles the recent research directions in using the newly emerged technologies during the era of COVID-19 pandemic. It mainly focuses on using emerging technologies and their impact on health care, education, and society. It also provides insights into the current challenges and constraints in using technologies during the era of COVID-19 pandemic and exposes new opportunities for future research in the domain.

Coronavirus Drug Discovery, Volume Three: Druggable Targets and In Silico Update presents comprehensive information on drug discovery against COVID-19. Chapters in Part One of this volume describe the various druggable targets and associated signaling pathways for effective targeting of SARS-CoV-2. In Part Two, chapters discuss the various computational approaches and in silico studies against SARS-CoV-2. Written by global team of experts, this book is an excellent resource that will be extremely useful to drug developers, medicinal chemists, pharmaceutical companies in R&D, research institutes in both academia and industry, and the National Library of Medicines and Health. In addition, agencies such as the National Institutes of Health, Centers for Disease Control and Prevention, World Health Organization, European Medicines Agency, the US Food and Drug Administration, and all others involved in drug discovery against COVID-19 will find this book useful. - Discusses the pathogenic mechanisms of SARS-CoV-2 and druggable targets - Reviews the various signaling pathways associated with SAR-CoV-2 as possible druggable targets - Presents computational approaches and in silico studies against SARS-CoV-2

Coronavirus Drug Discovery, Volume Two: Antiviral Agents from Natural Products and Nanotechnological Applications presents detailed information on drug discovery against COVID-19. Sections in this volume present chapters that focus on the various antiviral agents from natural products that have the propensity to be used as chemical scaffolds for the development of drugs against COVID-19. Also captured are the dietary sources of antioxidant bioactives that may help boost the immune system for the management of COVID-19. Other chapters describe the application of nanotechnology for efficient and effective delivery of drugs against COVID-19. Written by global team of experts, this book is an excellent resource for drug developers, medicinal chemists, pharmaceutical companies in R&D and research institutes in both academia and industry. - Presents the various antiviral bioactive compounds from natural products - Discusses the roles of antioxidant in the prevention and management of COVID-19 - Details the application of nanotechnology for efficient and effective drug delivery

This comprehensive, practical guide presents an explanation of the latest techniques and methods in drug discovery, including: Genomics, proteomics, high-throughput screening, and systems biology Summaries of how these techniques and methods are used to discover new central nervous system agents, antiviral agents, respiratory drugs, oncology drugs, and more Specific approaches to drug discovery, including problems that are encountered, solutions to these problems, and limitations of various methods and techniques.

This book is well-structured book which consists of 31 full chapters. The book chapters' deal with the recent research problems in the areas of modeling, control and drug development, and it presents various techniques of COVID-19 outbreak prevention modeling. The book also concentrates on computational simulations that may help speed up the development of drugs to counter the novel coronavirus responsible for COVID-19. This is an open access book.

This publication gives an overview of the existing portfolio of EU-supported projects in the area of emerging and re-emerging infectious diseases (EID). There are 34 projects listed within.